Abstract: Urogenital sinus derived growth inhibitory factor is a protein having growth-inhibitory and antiprotease properties. The present invention relates to amino acid and nucleotide sequences for urogenital sinus derived growth inhibitory factor.

Abstract: The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to mammals. The antagonists may be used to reduce the activity of growth hormone in a mammal, especially one suffering from diabetes, diabetic retinopathy, diabetic nephropathy, a growth hormone secreting tumor, acromegaly, or gigantism.

Abstract: An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides a method of activating the Rse receptor by exposing a cell comprising the Rse receptor to exogenous gas6 polypeptide. Moreover, the present invention is directed to a method for enhancing the survival, proliferation or differentiation of a cell comprising a Rse receptor by exposing the cell to exogenous gas6 polypeptide. The types of cells which can be treated according to the method include glial cells such as Schwann cells.

Abstract: The present invention relates to physiologically-active derivatized natural and recombinant mammalian and human proteins and polypeptides. The invention provides chemical methods for derivatizing natural and recombinantly-derived proteins or polypeptides containing cysteine residues, either naturally or through site specific mutageneses. The pharmaceutical compositions containing the derivatized proteins and/or polypeptides are formulated to provide stable, long-acting compositions of such proteins and/or polypeptides, previously difficult to achieve.

Abstract: A DNA encoding a cell surface polypeptide of Porphyromonas gingivalis, and a recombinant DNA being a DNA having integrated the encoding DNA thereinto. The cell surface polypeptide of the periodontopathic organism useful for prophylaxis and diagnosis of periodontal diseases can be obtained in a large amount by a microorganism containing the recombinant DNA wherein the DNA was integrated.

Abstract: The present invention relates to polynucleotides encoding a novel human protein called Vascular Endothelial Growth Factor 2, or VEGF-2, as well as mature forms, proproteins, and fragments of VEGF-2. Also provided are vectors, host cells, and recombinant methods for producing VEGF-2. The invention further relates to polynucleotides that hybridize to polynucleotides of the present invention.

Abstract: The recombinant production of PDGF-AB in mammalian cells is disclosed by means of a bicistronic vector system in which an IRES sequence is located between the first and second cistrons and in which the B chain coding gene is located in the first cistron. The disclosed expression unit allows the equilmolar expression of the A and B polypeptide chains.

Abstract: Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

Abstract: The present invention discloses a novel cDNA isolated from human osteoclastoma tissue which encodes a novel polypeptide identified herein as Extracellular/Epidermal Growth Factor HCABA58X owing in part to the presence in its amino acid sequence of epidermal growth factor (EGF) domains characteristic of the EGF family of polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides. Also disclosed are antagonists against such polypeptides and their uses. Also disclosed are diagnostic assays for detecting altered levels of the polypeptides of the present invention and mutations in the nucleic acid sequences which encode such polypeptides.

Abstract: Polypeptide growth factors, termed PDFs, are described which are derived from placental tissue and promote the proliferation, growth and survival of prostate cells and epithelial cells. Nucleic acid molecules encoding the polypeptides are also described which are useful in recombinant methods for the production of the polypeptides.

Abstract: Pharmaceutical compositions containing hGH stabilized by means of saccharose. The formulation is particularly suitable for stabilizing a lyophilisate of recombinant hGH.

Abstract: Disclosed are interleukin-6 receptor agonists. These receptor agonists were enerated by mutating amino acid positions 175, 176, 177, 181, and/or 183 of human interleukin-6.

Abstract: An analytical method for detecting the presence poly-beta-hydroxybutyrate (PHB), which can be used as an indicator of atherosclerotic risk is disclosed. In the method, antibodies to PHB are used to detect the PHB.

Abstract: Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.

Abstract: This invention relates to composite somatotropin peptides comprising somatotropin epitopic amino acid sequences, and fusion proteins thereof, useful in potentiating growth hormone activity. Also disclosed are vectors and host cells useful in the recombinant production of such molecules. Vaccines containing the composite somatotropin peptides and fusion proteins of the present invention, and methods of using the same, are disclosed.

Abstract: The present invention relates to a novel FGF-5 analogous protein derived from mature mRNA formed by directly binding exon 1 to exon 3 in the splicing of a gene coding for FGF-5 protein as well as to a pharmaceutical composition containing the same as an active ingredient. The pharmaceutical composition containing the novel FGF-5 analogous protein of the present invention as an active ingredient can regulate physiological functions of FGF-5, such as regulation of restoration or development of hairs on the head and body, regulation of trophic and functional regulation in the brain and nervous system, proliferation of fibroblasts, etc.

Abstract: The invention relates to stable compositions of proteins and related methods wherein a protein capable of transitioning into the molten globular state is contacted with a negatively charged lipid vesicle, thereby stabilizing the protein against thermally-induced aggregation, denaturation, and loss of activity. The protein:phospholipid complex directly stabilizes the secondary and tertiary structure of the protein, and the compositions are useful in high temperature formulations and in novel delivery vehicles.

Abstract: The present invention teaches a method of identifying agents that affect NHE3. Specifically, these methods comprise the steps of obtaining DNA encoding all or a portion of human NHE3, introducing that DNA into a recipient host cell whereby the host cell can perform Na+/H+ exchange, applying agents to the host cell, and assessing whether the agents affect Na+/H+ exchange.

Abstract: A novel protein, fibroblast growth factor homologous factor-1 (FHF-1), the polynucleotide sequence encoding FHF-1, and the deduced amino acid sequence are disclosed. Also disclosed are diagnostic and therapeutic methods of using the FHF-1 polypeptide and polynucleotide sequences and antibodies which specifically bind to FHF-1.

Abstract: The present invention is directed to a biologically active CSF-1 dimer comprising a first CSF-1 monomer and a second CSF-1 monomer, wherein at least one of the monomers is truncated at the C-terminus after residue position 223. The dimers also include point mutations in one or both of the CSF-1 monomer. The invention also includes pharmaceutical compositions that comprise the CSF-1 dimer in a pharmaceutical excipient.